IMVT

Immunovant (IMVT)

Immunovant Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMVT

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/03/12	20 : 30	GlobeNewswire Inc.	Immunovant Awarded U.S. Patent for IMVT-1402	NASDAQ:IMVT	Immunovant Inc
2024/02/24	06 : 21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/02/24	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/02/24	06 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/02/14	22 : 47	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:IMVT	Immunovant Inc
2024/02/12	21 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMVT	Immunovant Inc
2024/02/12	21 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMVT	Immunovant Inc
2024/01/30	06 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/01/20	06 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/01/16	21 : 29	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/01/13	06 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/01/10	06 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/01/10	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2024/01/09	22 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMVT	Immunovant Inc
2024/01/03	22 : 00	GlobeNewswire Inc.	Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:IMVT	Immunovant Inc
2023/12/21	07 : 40	Dow Jones News	Immunovant Gets Positive Data From Graves' Disease Treatment Trial	NASDAQ:IMVT	Immunovant Inc
2023/12/21	06 : 37	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMVT	Immunovant Inc
2023/12/21	06 : 30	GlobeNewswire Inc.	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	NASDAQ:IMVT	Immunovant Inc
2023/12/21	06 : 30	GlobeNewswire Inc.	Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	NASDAQ:IMVT	Immunovant Inc
2023/11/28	21 : 43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMVT	Immunovant Inc
2023/11/28	21 : 00	GlobeNewswire Inc.	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	NASDAQ:IMVT	Immunovant Inc
2023/11/28	21 : 00	GlobeNewswire Inc.	Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	NASDAQ:IMVT	Immunovant Inc
2023/11/25	04 : 55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2023/11/25	04 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2023/11/25	04 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2023/11/25	04 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMVT	Immunovant Inc
2023/11/13	22 : 00	GlobeNewswire Inc.	Immunovant to Present at Upcoming Investor Conferences	NASDAQ:IMVT	Immunovant Inc
2023/11/09	22 : 49	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:IMVT	Immunovant Inc
2023/11/09	21 : 13	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMVT	Immunovant Inc
2023/11/09	21 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMVT	Immunovant Inc